GeNO Healthcare, which is developing inhaled nitric oxide products to treat pulmonary and cardiac diseases, withdrew its plans for an initial public offering on Tuesday. The company originally filed for a $50 million IPO in December 2013. GeNO's nitric oxide cartridges can be used to treat pulmonary arterial hypertension, and was expected to enter Phase 3 trials by the 2H14 and submit an NDA by the 2H15.
The Waltham, MA-based company was founded in 2006 and had planned to list on the NASDAQ under the symbol GNO. Jefferies and Stifel were set to be the joint bookrunners on the deal.
